122 related articles for article (PubMed ID: 38199869)
1. Postchemotherapy Retroperitoneal Lumpectomy in Patients with Nonseminoma Testicular Cancer: A Nationwide Study.
Rosenvilde JJ; Lauritsen J; Bandak M; Wagner T; Agerbæk M; Dysager L; Aagaard M; Daugaard G
Eur Urol Oncol; 2024 Jun; 7(3):589-596. PubMed ID: 38199869
[TBL] [Abstract][Full Text] [Related]
2. Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group.
Gerdtsson A; Thor A; Grenabo Bergdahl A; Almås B; Håkansson U; Törnblom M; Negaard HFS; Glimelius I; Halvorsen D; Karlsdóttir Á; Sagstuen Haugnes H; Engen Andreassen K; Melsen Larsen S; Holmberg G; Wahlqvist R; Tandstad T; Cohn-Cedermark G; Ståhl O; Kjellman A
Eur Urol Oncol; 2022 Apr; 5(2):235-243. PubMed ID: 33750683
[TBL] [Abstract][Full Text] [Related]
3. Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group.
Gerdtsson A; Håkansson U; Törnblom M; Jancke G; Negaard HFS; Glimelius I; Halvorsen D; Karlsdóttir Á; Haugnes HS; Andreassen KE; Larsen SM; Holmberg G; Wahlqvist R; Tandstad T; Cohn-Cedermark G; Ståhl O; Kjellman A
Eur Urol Oncol; 2020 Jun; 3(3):382-389. PubMed ID: 31506250
[TBL] [Abstract][Full Text] [Related]
4. Preservation of Ejaculatory Function After Postchemotherapy Retroperitoneal Lymph Node Dissection (PC-RPLND) in Patients With Testicular Cancer: Template vs. Bilateral Resection.
Hiester A; Nini A; Fingerhut A; Große Siemer R; Winter C; Albers P; Lusch A
Front Surg; 2018; 5():80. PubMed ID: 30705885
[No Abstract] [Full Text] [Related]
5. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.
Steiner H; Leonhartsberger N; Stoehr B; Peschel R; Pichler R
Eur Urol; 2013 Jun; 63(6):1013-7. PubMed ID: 23021090
[TBL] [Abstract][Full Text] [Related]
6. Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer.
Li R; Duplisea JJ; Petros FG; González GMN; Tu SM; Karam JA; Huynh TT; Ward JF
Eur Urol Oncol; 2021 Aug; 4(4):651-658. PubMed ID: 31412007
[TBL] [Abstract][Full Text] [Related]
7. [Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours].
Paffenholz P; Pfister D; Heidenreich A
Urologe A; 2016 May; 55(5):632-40. PubMed ID: 26820659
[TBL] [Abstract][Full Text] [Related]
8. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection.
Heidenreich A; Pfister D; Witthuhn R; Thüer D; Albers P
Eur Urol; 2009 Jan; 55(1):217-24. PubMed ID: 18926622
[TBL] [Abstract][Full Text] [Related]
9. Nerve-sparing Robot-assisted Retroperitoneal Lymph Node Dissection: The Monoblock Technique.
Afferi L; Baumeister P; Fankhauser C; Mordasini L; Moschini M; Aschwanden F; Mattei A
Eur Urol Open Sci; 2021 Oct; 32():1-7. PubMed ID: 34667953
[TBL] [Abstract][Full Text] [Related]
10. The intraoperative assessment of the effectiveness of computed tomography in the detection of the residual mass of the retroperitoneal space in patients with nonseminoma testicular tumors after chemotherapy.
Jaszczyński J; Chłosta P; Faron P; Strach A; Jakubik P; Wilk W; Luczyńska E; Anioł J; Skotnicki P; Jakubowicz J; Stelmach A
Pol J Radiol; 2011 Apr; 76(2):22-4. PubMed ID: 22802826
[TBL] [Abstract][Full Text] [Related]
11. Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor.
Nason GJ; Jewett MAS; Bostrom PJ; Goldberg H; Hansen AR; Bedard PL; Sturgeon J; Warde P; Chung P; Anson-Cartwright L; Sweet J; Atenafu EG; O'Malley M; Hamilton RJ
Eur Urol Oncol; 2021 Apr; 4(2):289-296. PubMed ID: 32907779
[TBL] [Abstract][Full Text] [Related]
12. Postchemotherapy retroperitoneal residual mass resection for germ cell testicular tumors: a single-center experience.
Kalemci S; Kizilay F; Ergun KE; Aliyev B; Simsir A
Rev Assoc Med Bras (1992); 2022 Apr; 68(4):524-529. PubMed ID: 35649078
[TBL] [Abstract][Full Text] [Related]
13. Outcomes following retroperitoneal lymph node dissection in postchemotherapy residual masses in advanced testicular germ cell tumors.
Singh P; Yadav S; Mahapatra S; Seth A
Indian J Urol; 2016; 32(1):40-4. PubMed ID: 26941493
[TBL] [Abstract][Full Text] [Related]
14. A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma.
Leão R; Nayan M; Punjani N; Jewett MAS; Fadaak K; Garisto J; Lewin J; Atenafu EG; Sweet J; Anson-Cartwright L; Boström P; Chung P; Warde P; Bedard PL; Bagrodia A; Freifeld Y; Power N; Winquist E; Hamilton RJ
Eur Urol Focus; 2018 Dec; 4(6):995-1001. PubMed ID: 29428550
[TBL] [Abstract][Full Text] [Related]
15. Postchemotherapy robotic retroperitoneal lymph node dissection for non-seminomatous germ cell tumors in the lateral decubitus position: oncological and functional outcomes.
Kordan Y; Köseoğlu E; Esen B; Özkan A; Kiremit MC; Kılıç M; Esen T
World J Urol; 2023 Apr; 41(4):1101-1107. PubMed ID: 36806014
[TBL] [Abstract][Full Text] [Related]
16. Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma.
Sharma P; Sverrisson EF; Zargar-Shoshtari K; Fishman MN; Sexton WJ; Dickinson SI; Spiess PE; Poch MA; Gilbert SM; Pow-Sang JM
Can J Urol; 2015 Aug; 22(4):7882-9. PubMed ID: 26267026
[TBL] [Abstract][Full Text] [Related]
17. Contemporary management of postchemotherapy testis cancer.
Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
[TBL] [Abstract][Full Text] [Related]
18. Major complications of post-chemotherapy retroperitoneal lymph node dissection in a contemporary cohort of patients with testicular cancer and a review of the literature.
Ruf CG; Krampe S; Matthies C; Anheuser P; Nestler T; Simon J; Isbarn H; Dieckmann KP
World J Surg Oncol; 2020 Sep; 18(1):253. PubMed ID: 32972425
[TBL] [Abstract][Full Text] [Related]
19. Expression of programmed death ligand-1 (PD-L1) in metastatic and postchemotherapy viable testicular germ cell tumors.
Al-Hogbani M; Duguay J; Wagner DC; Haferkamp A; Joubert P; Frees S; Rendon R; Power N; Périgny M; Toren P
Urol Oncol; 2021 May; 39(5):303.e1-303.e8. PubMed ID: 33685799
[TBL] [Abstract][Full Text] [Related]
20. Surveillance of postchemotherapy subcentimeter residual retroperitoneal mass in metastatic nonseminomatous germ cell tumor: Does how you measure matter?
Cotner CE; Hilton S; Mamtani R; Guzzo T; Vaughn DJ
Urol Oncol; 2021 Feb; 39(2):136.e11-136.e17. PubMed ID: 33308971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
